報道指中國完成全球首支Omicron滅活疫苗臨牀第一劑接種
據《上觀新聞》報道,由國藥集團中國生物北京生物製品研究所研發的奧密克戎變異株(Omicron)新冠病毒滅活疫苗臨牀研究,於5月1日正式在浙江省杭州市完成第一劑接種。這是全球首支針對奧密克戎變異株進入臨牀試驗的新冠病毒滅活疫苗。此次奧株新冠病毒滅活疫苗臨牀研究,將採用非隨機、開放、外部對照的研究形式。
此次在樹蘭(杭州)醫院開展臨牀研究的奧株疫苗需要接種兩劑,將評價奧株疫苗在未接種新冠病毒疫苗18歲及以上人羣中的安全性和免疫原性。此臨牀研究數據獲批後,未接種過新冠疫苗的空白人羣可直接接種奧株疫苗。(ta/w) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.